Human post-infection serological response to the spike and nucleocapsid proteins of SARS-CoV-2
© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd..
To inform seroepidemiological studies, we characterized the IgG- responses in COVID-19 patients against the two major SARS-CoV-2 viral proteins, spike (S) and nucleocapsid (N). We tested 70 COVID-19 sera collected up to 85 days post-symptom onset and 230 non-COVID-19 sera, including 27 SARS sera from 2003. Although the average SARS-CoV-2 S and N-IgG titers were comparable, N-responses were more variable among individuals. S- and N-assay specificity tested with non-COVID-19 sera were comparable at 97.5% and 97.0%, respectively. Therefore, S will make a better target due to its lower cross-reactive potential and its' more consistent frequency of detection compared to N.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Influenza and other respiratory viruses - 15(2021), 1 vom: 16. Jan., Seite 7-12 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xiao, Cheng [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 15.01.2021 Date Revised 07.12.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1111/irv.12798 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM31417947X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM31417947X | ||
| 003 | DE-627 | ||
| 005 | 20231225152158.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1111/irv.12798 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM31417947X | ||
| 035 | |a (NLM)32844604 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xiao, Cheng |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Human post-infection serological response to the spike and nucleocapsid proteins of SARS-CoV-2 |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.01.2021 | ||
| 500 | |a Date Revised 07.12.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd. | ||
| 520 | |a To inform seroepidemiological studies, we characterized the IgG- responses in COVID-19 patients against the two major SARS-CoV-2 viral proteins, spike (S) and nucleocapsid (N). We tested 70 COVID-19 sera collected up to 85 days post-symptom onset and 230 non-COVID-19 sera, including 27 SARS sera from 2003. Although the average SARS-CoV-2 S and N-IgG titers were comparable, N-responses were more variable among individuals. S- and N-assay specificity tested with non-COVID-19 sera were comparable at 97.5% and 97.0%, respectively. Therefore, S will make a better target due to its lower cross-reactive potential and its' more consistent frequency of detection compared to N | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a epidemiology | |
| 650 | 4 | |a nucleocapsid | |
| 650 | 4 | |a serology | |
| 650 | 4 | |a spike | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Coronavirus Nucleocapsid Proteins |2 NLM | |
| 650 | 7 | |a Phosphoproteins |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 650 | 7 | |a nucleocapsid phosphoprotein, SARS-CoV-2 |2 NLM | |
| 650 | 7 | |a spike protein, SARS-CoV-2 |2 NLM | |
| 700 | 1 | |a Ling, Shiman |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Minshan |e verfasserin |4 aut | |
| 700 | 1 | |a Deng, Zhenxuan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Liping |e verfasserin |4 aut | |
| 700 | 1 | |a Zhu, Airu |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Yi |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Yong |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Fangmei |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Qiubao |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Lihan |e verfasserin |4 aut | |
| 700 | 1 | |a Ye, Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Xiaoqing |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Yimin |e verfasserin |4 aut | |
| 700 | 1 | |a Zhao, Jincun |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zifeng |e verfasserin |4 aut | |
| 700 | 1 | |a Cowling, Benjamin J |e verfasserin |4 aut | |
| 700 | 1 | |a Webby, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a Zanin, Mark |e verfasserin |4 aut | |
| 700 | 1 | |a Wong, Sook-San |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Influenza and other respiratory viruses |d 2007 |g 15(2021), 1 vom: 16. Jan., Seite 7-12 |w (DE-627)NLM176605215 |x 1750-2659 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2021 |g number:1 |g day:16 |g month:01 |g pages:7-12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1111/irv.12798 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2021 |e 1 |b 16 |c 01 |h 7-12 | ||